SANOFI-AVENTIS SINGAPORE PTE. LTD.

**4.1 THERAPEUTIC INDICATIONS** Primary Hypercholesterolaemia/Homozygous Familial Hypercholesterolaemia (HoFH) Suvezen is indicated for substitution therapy in adult patients who are adequately controlled with rosuvastatin and ezetimibe given concurrently at the same dose level as in the fixed combination, but as separate products, as adjunct to diet for treatment of primary hypercholesterolaemia (heterozygous familial and non-familial) or homozygous familial hypercholesterolaemia.

**4.1 Therapeutic Indications** SARCLISA is indicated: - in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy. - in combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three prior therapies (see section 5.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_).

**1 INDICATIONS AND USAGE** DUPIXENT is indicated for the following diseases: **1.1 Atopic Dermatitis** DUPIXENT is indicated for the treatment of patients aged 6 years and older with moderate-to-severe atopic dermatitis who require chronic treatment and whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids. **1.2 Asthma** DUPIXENT is indicated in patients 6 years and older as an add-on maintenance treatment for severe asthma with type 2 inflammation characterized by elevated blood eosinophils and/or elevated FeNO. DUPIXENT is indicated as maintenance therapy for oral corticosteroid-dependent asthma. **1.3 Chronic Rhinosinusitis with Nasal Polyposis** DUPIXENT is indicated as an add-on maintenance treatment in adult patients with inadequately controlled severe chronic rhinosinusitis with nasal polyposis (CRSwNP).

<p><strong>Therapeutic indications</strong></p> <p>MenQuadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by <em>Neisseria meningitidis</em> serogroups A, C, W, and Y.</p> <p>The use of this vaccine should be in accordance with available official recommendations.</p>

<p><strong>THERAPEUTIC INDICATIONS:</strong></p> <p>Treatment of essential hypertension.<br> Aprovasc&reg; is indicated in the treatment of hypertension in adult patients in whom blood pressure is not adequately controlled on irbesartan or amlodipine monotherapy.</p>

<p><strong>THERAPEUTIC INDICATIONS:</strong></p> <p>Treatment of essential hypertension.<br> Aprovasc&reg; is indicated in the treatment of hypertension in adult patients in whom blood pressure is not adequately controlled on irbesartan or amlodipine monotherapy.</p>

**4.1 Therapeutic indications** This vaccine is indicated in the joint prevention of diphtheria, tetanus, pertussis and poliomyelitis according to official recommendations: - for primary vaccination in infants from the age of 2 months, - for booster vaccination

<p><strong>4.1 Therapeutic Indications</strong></p> <p>PENTAXIM (DTaP-IPV-Hib) is indicated for the joint prevention of diphtheria, tetanus, pertussis, poliomyelitis and invasive <em>Haemophilus influenzae</em> type b infections (meningitis, septicaemia, cellulitis, arthritis, epiglottitis, etc.,),</p> <ul> <li>for primary vaccination in infants from the age of 2 months,</li> <li>for booster vaccination, one year after primary vaccination during the second year of life.</li> </ul> <p>This vaccine does not protect against infections caused by the other types of <em>Haemophilus influenzae</em> nor against meningitis caused by other micro-organisms.</p>

**Therapeutic Indications** ZALTRAP in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy is indicated in adults with metastatic colorectal cancer (MCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen.